v3.26.1
Condensed Consolidated Statements of Shareholders’ Equity / (Deficit) - USD ($)
$ in Thousands
Total
At-The-Market Offering
ADDITIONAL PAID-IN CAPITAL
ADDITIONAL PAID-IN CAPITAL
At-The-Market Offering
ACCUMULATED OTHER COMPREHENSIVE LOSS
ACCUMULATED DEFICIT
Ordinary shares
ORDINARY SHARES
Ordinary shares
ORDINARY SHARES
At-The-Market Offering
Beginning balance (in shares) at Dec. 31, 2024             68,552,215  
Beginning balance at Dec. 31, 2024 $ 154,695   $ 704,919   $ (16,194) $ (534,732) $ 702  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of ordinary shares, net of issuance costs (in shares)             24,014,728  
Issuance of ordinary shares, net of issuance costs 54,816   54,583       $ 233  
Exercise of share options (in shares)             164,422  
Exercise of share options 2           $ 2  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             116,961  
Issuance of ordinary shares to settle vested restricted stock units 0   (1)       $ 1  
Share-based compensation expense 3,935   3,935          
Unrealized gain (loss) on foreign currency translation (117)       (117)      
Net loss (17,864)         (17,864)    
Ending balance (in shares) at Mar. 31, 2025             92,848,326  
Ending balance at Mar. 31, 2025 195,467   763,436   (16,311) (552,596) $ 938  
Beginning balance (in shares) at Dec. 31, 2024             68,552,215  
Beginning balance at Dec. 31, 2024 154,695   704,919   (16,194) (534,732) $ 702  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Unrealized gain (loss) on foreign currency translation 1,612              
Net loss (56,267)              
Ending balance (in shares) at Jun. 30, 2025             93,586,348  
Ending balance at Jun. 30, 2025 162,555   767,190   (14,582) (590,999) $ 946  
Beginning balance (in shares) at Mar. 31, 2025             92,848,326  
Beginning balance at Mar. 31, 2025 195,467   763,436   (16,311) (552,596) $ 938  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of share options (in shares)             682,682  
Exercise of share options 9   2       $ 7  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             9,375  
Issuance of ordinary shares to settle vested restricted stock units 0              
Issuance of ordinary shares under the employee share purchase plan (in shares)             45,965  
Issuance of ordinary shares under the employee share purchase plan 157   156       $ 1  
Share-based compensation expense 3,596   3,596          
Unrealized gain (loss) on foreign currency translation 1,729       1,729      
Net loss (38,403)         (38,403)    
Ending balance (in shares) at Jun. 30, 2025             93,586,348  
Ending balance at Jun. 30, 2025 $ 162,555   767,190   (14,582) (590,999) $ 946  
Beginning balance (in shares) at Dec. 31, 2025 96,085,785           96,085,785  
Beginning balance at Dec. 31, 2025 $ (52,848)   783,562   (14,789) (822,594) $ 973  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of ordinary shares, net of issuance costs (in shares)             17,500,000  
Issuance of ordinary shares, net of issuance costs 131,286   131,097       $ 189  
Exercise of share options (in shares)             6,333  
Exercise of share options 24   23       $ 1  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             170,558  
Issuance of ordinary shares to settle vested restricted stock units 0   (2)       $ 2  
Issuance of ordinary shares to settle warrant exercised (in shares)             21,160,619  
Issuance of ordinary shares to settle warrant exercised 154,133   153,905       $ 228  
Share-based compensation expense 2,896   2,896          
Unrealized gain (loss) on foreign currency translation (6)       (6)      
Net loss 91,202         91,202    
Ending balance (in shares) at Mar. 31, 2026             134,923,295  
Ending balance at Mar. 31, 2026 $ 326,687   1,071,481   (14,795) (731,392) $ 1,393  
Beginning balance (in shares) at Dec. 31, 2025 96,085,785           96,085,785  
Beginning balance at Dec. 31, 2025 $ (52,848)   783,562   (14,789) (822,594) $ 973  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Unrealized gain (loss) on foreign currency translation 48              
Net loss $ (162,592)              
Ending balance (in shares) at Jun. 30, 2026 135,722,306           135,722,306  
Ending balance at Jun. 30, 2026 $ 84,533   1,083,059   (14,741) (985,186) $ 1,401  
Beginning balance (in shares) at Mar. 31, 2026             134,923,295  
Beginning balance at Mar. 31, 2026 326,687   1,071,481   (14,795) (731,392) $ 1,393  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of ordinary shares, net of issuance costs (in shares)               108,000
Issuance of ordinary shares, net of issuance costs   $ 1,397   $ 1,396       $ 1
Exercise of share options (in shares)             136,883  
Exercise of share options 1,127   1,126       $ 1  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             9,375  
Issuance of ordinary shares to settle vested restricted stock units 0              
Issuance of ordinary shares under the employee share purchase plan (in shares)             29,753  
Issuance of ordinary shares under the employee share purchase plan 160   160          
Issuance of ordinary shares to settle warrant exercised (in shares)             515,000  
Issuance of ordinary shares to settle warrant exercised 5,114   5,108       $ 6  
Share-based compensation expense 4,027   4,027          
Shares tendered for withholding taxes (239)   (239)          
Unrealized gain (loss) on foreign currency translation 54       54      
Net loss $ (253,794)         (253,794)    
Ending balance (in shares) at Jun. 30, 2026 135,722,306           135,722,306  
Ending balance at Jun. 30, 2026 $ 84,533   $ 1,083,059   $ (14,741) $ (985,186) $ 1,401